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Hillard M. Lazarus,1 Jeanette Carreras,2 Christian Boudreau,3 Fausto R. Loberiza, Jr.,4
James O. Armitage,4 Brian J. Bolwell,5 Cesar O. Freytes,6 Robert Peter Gale,7 John Gibson,8
Gregory A. Hale,9 David J. Inwards,10 Charles F. LeMaistre,11 Dipnarine Maharaj,12
David I. Marks,13 Alan M. Miller,14 Santiago Pavlovsky,15 Harry C. Schouten,16 Koen van
Besien,17 Julie M. Vose,4 Jacob D. Bitran,18 Issa F. Khouri,19 Philip L. McCarthy,20
Hongmei Yu,21 Philip Rowlings,22 Derek S. Serna,2 Mary M. Horowitz,2 J. Douglas Rizzo2To compare the clinical outcomes of older (age $55 years) non-Hodgkin lymphoma (NHL) patients with
younger NHL patients (\55 years) receiving autologous hematopoietic cell transplantation (HCT) while ad-
justing for patient-, disease-, and treatment-related variables, we compared autologous HCT outcomes in
805 NHL patients aged $55 years to 1949 NHL patients\55 years during the years 1990–2000 using
data reported to the Center for International Blood and Marrow Transplant Research (CIBMTR). In multi-
variate analysis, older patients with aggressive histologies were 1.86 times (95% confidence interval [CI] 1.43-
2.43, P\.001) more likely than younger patients to experience treatment-related mortality (TRM). Relative
death risks were 1.33 times (CI 1.04-1.71, P 5 .024) and 1.50 times (CI 1.33-16.9, P\.001) higher in older
compared to younger patients with follicular grade I/II and aggressive histologies, respectively. Autologous
HCT in older NHL patients is feasible, but most disease-related outcomes are statistically inferior to younger
patients. Studies addressing supportive care particular to older patients, who are most likely to benefit from
this approach, are recommended.
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1324 Biol Blood Marrow Transplant 14:1323-1333, 2008H. M. Lazarus et al.[1,2]. Older age is a well-recognized poor prognostic
factor [3,4]. Reluctance to offer autologous hemato-
poietic cell transplantation (HCT) to older patients
with hematologic malignancies is reinforced by
a high treatment-related mortality (TRM). Several
studies published more than a decade ago showed a di-
rect correlation with increased age and higher likeli-
hood for hepatic veno-occlusive disease (VOD),
interstitial pneumonitis, and other fatal complications
[5,6]. Additionally, Weaver et al. [7] reported a large
study of community cancer center patients receiving
autologous HCT, for various malignant disorders
where 9.5% of patients .60 years died of treatment-
related causes within 100 days of HCT compared
with 3% of younger patients. It is unclear what selec-
tion criteria were used when considering HCT in the
elderly population included in this study. The median
age of autologous HCT in several recent series is 35 to
45 years [6,8-12].
We performed a multicenter retrospective study
using an observational database to determine the effect
of age (ie, \55 years versus $55 years old) on the
short-term and long-term outcomes of NHL patients
who have undergone an autologous HCT. Although
the literature commonly reports age 60 years as a cut-
off, in part reflecting the prognostic index derived
from a nontransplant data set [3], we chose 55 years
as the optimal value to demonstrate the largest differ-
ences for individuals from 2 age groups (vide infra).
Further, some reports for NHL HCT procedures
combine results for indolent and aggressive histolo-
gies. Our main study objective was to compare overall
survival (OS), disease-free survival (DFS), TRM, and
relapse rates between younger and older patients, for
patients with indolent (follicular center cell grade I
and II) and aggressive lymphoma (follicular III, diffuse
large cell, and immunoblastic). We also sought to
identify patient-, disease-, and treatment-related fac-
tors correlated with outcome. These data will provide
important information for treatment decisions for
NHL patients being considered for autologous HCT.PATIENTS AND METHODS
Center for International Blood and Marrow
Transplant Research (CIBMTR)
The CIBMTR is a research affiliation of the Inter-
national Bone Marrow Transplant Registry (IBMTR),
Autologous Blood and Marrow Transplant Registry
(ABMTR), and the National Marrow Donor Program
(NMDP), which comprises a voluntary working group
of more than 450 transplant centers worldwide that
contribute detailed data on consecutive allogeneic
and autologous transplants to a Statistical Center at
the Health Policy Institute of the Medical College of
Wisconsin in Milwaukee or the NMDP CoordinatingCenter in Minneapolis. Participating centers are re-
quired to report all consecutive transplants; compli-
ance is monitored by on-site audits. Subjects are
followed longitudinally, with yearly follow-up. Com-
puterized checks for errors, physicians’ review of sub-
mitted data and on-site audits of participating centers
ensure data quality. Observational studies conducted
by the CIBMTR are done with a waiver of informed
consent, and in compliance with HIPAA regulations,
as determined by the institutional review board and
the Privacy Officer of the Medical College of Wisconsin.
The CIBMTR collects data at 2 levels: registration
and research. Registration data include disease type,
age, sex, pretransplant disease stage and chemotherapy
responsiveness, date of diagnosis, graft type (bone mar-
row- and/or blood-derived stem cells), high-dose con-
ditioning regimen, posttransplant disease progression
and survival, development of a new malignancy, and
cause of death. Requests for data on progression or
death for registered patients are at 6-month intervals.
All CIBMTR teams contribute Registration data.
Research data are collected on a subset of registered
patients selected using a weighted randomization
scheme and include detailed disease, and pre- and post-
transplant clinical information. Based on data collected
in the Centers for Disease Control Hospital Surveys
[13,14] and the U.S. Government Accounting Office
[15,16] and worldwide surveys of transplant activity,
approximately 40% of allogeneic transplants worldwide
and more than 50% of autologous HCTs in North and
South America are registered with the CIBMTR.
Patients
Between January 1, 1990, and December 31, 2000,
8244 NHL (histology limited to indolent and aggres-
sive) patients who received autologous HCT were reg-
istered with the CIBMTR. Of these, a total of 2754
(33%) NHL patients have complete research data
and were included in the study. Forty-eight patients
were excluded because they were younger than 18
years prior to transplantation. A total of 1949 patients
were less than age 55 years at time of transplantation,
whereas 805 were at least 55 years old. Patients were
reported to the CIBMTR by 176 centers in 10 differ-
ent countries. To assure that the research patients
were representative of all registered patients, demo-
graphics, relapse, and survival rates between research
and registered patients were compared; no differences
were noted. Median follow-up of survivors after autol-
ogous HCT was 92 months (range:\1-198 months)
for patients\55 years and 83 months (range: 2-196
months) for patients $55 years.Study Endpoints
Primary outcomes studied were TRM, relapse,
treatment failure (inverse of DFS), and OS. TRM was
Table 1. Characteristics of NHL Patients Undergoing Autologous HCT from 1990 to 2000 and Reported to the CIBMTR
Follicular Grade I/II Follicular Grade III DLBCL Immunoblastic NHL
<55 Years $55 Years <55 Years $55 Years
Variable N (%) N (%) N (%) N (%) P-Value*
Number of patients 615 173 1334 632
Age, median (range), years 46 (19-55) 60 (55-72) 44 (18-55) 61 (55-73)
Male sex 339 (55) 105 (61) 776 (58) 367 (58) .48
Karnofsky performance score at transplant <.001
<90 145 (25) 41 (24) 475 (37) 237 (38)
$90 440 (75) 132 (76) 819 (63) 381 (62)
Missing 30 0 40 14
Disease stage at diagnosis <.001
I or II 87 (14) 41 (24) 479 (36) 221 (35)
III or IV 520 (85) 129 (74) 822 (62) 402 (64)
Unknown 8 (1) 3 (2) 33 (2) 9 (1)
B symptoms at diagnosis <.001
Absent 383 (62) 112 (65) 691 (52) 362 (57)
Present 193 (32) 39 (22) 552 (41) 211 (34)
Unknown 39 (6) 22 (13) 91 (7) 59 (9)
Disease status at transplant <.001
CR1 87 (16) 14 (9) 178 (15) 50 (8)
CR2+ 98 (18) 31 (21) 217 (18) 113 (19)
PIF-sensitive 118 (21) 27 (18) 236 (19) 69 (12)
PIF-resistant 18 (3) 4 (3) 78 (6) 22 (4)
PIF-untreated/unknown 10 (2) 0 13 (1) 3 (1)
REL-sensitive 165 (30) 53 (35) 343 (28) 243 (42)
REL-resistant 30 (5) 17 (11) 102 (9) 57 (10)
REL-untreated/unknown 28 (5) 4 (3) 53 (4) 25 (4)
Missing 61 23 114 50
Chemosensitivity at transplant .01
Sensitivity 479 (78) 137 (79) 976 (73) 498 (79)
Resistant 56 (9) 22 (13) 184 (14) 74 (12)
Untreated/not evaluable/unknown 80 (13) 14 ( 8) 174 (13) 60 (9)
Interval from diagnosis to transplant <.001
<12 months 126 (20) 34 (20) 613 (46) 172 (27)
$12 months 489 (80) 139 (80) 721 (54) 460 (73)
Graft type <.001
Bone marrow 191 (31) 38 (22) 398 (30) 113 (18)
Peripheral blood 424 (69) 135 (78) 936 (70) 519 (82)
Use of involved-field radiation 34 (6) 7 (4) 61 (5) 16 (3) .06
Use of TBI 280 (46) 59 (34) 320 (24) 120 (19) <.001
Conditioning regimen <.001
TBI 280 (46) 59 (34) 320 (24) 120 (19)
Cy+VP16 46 (7) 9 ( 5) 132 (10) 52 ( 8)
BCNU-based: BEAM/BEAC 170 (28) 64 (37) 643 (48) 315 (50)
Platinum based (no Cy) 24 (4) 10 (6) 64 (5) 29 (5)
Others 95 (15) 31 (18) 175 (13) 116 (18)
Year of transplantation <.001
1990-1994 327 (53) 56 (32) 528 (39) 168 (27)
1995-1996 130 (21) 44 (25) 334 (25) 165 (26)
1997-1998 104 (17) 46 (27) 302 (23) 174 (27)
1999-2000 54 (9) 27 (16) 170 (13) 125 (20)
In vitro purging performed 142 (23) 34 (20) 99 (7) 45 (7) <.001
G-CSF or GM-CSF to promote engraftment 450 (73) 129 (75) 1007 (75) 496 (78) .18
New malignancy .02
MDS/AML 8 (1) 1 (1) 9 (1) 6 (1)
Other leukemia 0 0 1 (<1) 0
Solid tumor 4 (1) 1 (1) 4 (<1) 8 ( 1)
Skin cancer 2 (<1) 1 (1) 0 1 (<1)
New malignancy, not specified 47 (8) 13 (7) 55 (4) 30 (5)
None 553 (90) 156 (90) 1261 (95) 584 (93)
Missing 1 1 4 3
Median follow-up of survivors, months 90 (3-180) 81 (2-155) 93 (1-198) 84 (3-196)
CR indicates complete remission; PIF, primary induction failure; TBI, total body irradiation; Cy, cyclophosphamide; GF, growth factors; G-CSF, granu-
locyte-colony stimulating factor; GM-CSF, granulocyte-macrophage colony stimulating factor; NHL, non-Hodgkin lymphoma; CIBMTR, Center for
International Blood and Marrow Transplant Research.
Follow-up completeness index 5 92% (overall); 91% (<55 years); 94% ($55 years).
*The chi-square test was used for discrete covariates; the Kruskal-Wallis test was used for continuous covariates.
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Figure 1. Cumulative incidence of TRM and relapse after autologous
HCTs for follicular grade I/II NHL patients aged \55 years versus
$55 years.
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Figure 3. Cumulative incidence of TRM and relapse after autologous
HCTs for follicular grade III/diffuse large B cell/immunoblastic NHL pa-
tients aged\55 years versus $55 years.
1326 Biol Blood Marrow Transplant 14:1323-1333, 2008H. M. Lazarus et al.defined as death in continuous complete remission
(CR) or any death occurring\28 days after transplant.
Patients who never achieved CR were considered to re-
lapse at day 28. Patients with recurrent lymphoma were
censored for TRM at the time of relapse. Likewise,
those alive in remission were censored for relapse at
the last follow-up evaluation. For DFS, patients were
considered treatment failures at the time of relapse or
at the time of death from any cause. Patients alive in
continuous complete remission were censored at last
follow-up evaluation. OS was defined as the interval be-
tween transplant and death from any cause. Surviving
patients were censored at the date of last contact.Statistical Methods
Univariate probabilities of TRM and relapse were
computed using cumulative incidence to accommo-
date competing risks. Univariate probabilities of treat-
ment failure (inverse of DFS) and OS were computed
using the Kaplan-Meier estimator [17].
Statistical techniques, that is, Contal and O’Quig-
ley [18] and maximum likelihood theory, were used to
determine the optimal categorization of age groups
among cut-off points including ages 50, 55, 60, and
65 years. The choice of 55 years produced the optimalP
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Figure 2. Cumulative incidence of DFS and OS after autologous HCTs
for follicular grade I/II NHL patients aged\55 years versus $55 years.age cutoff value based on these statistical methods; op-
timal in the sense that 55 years maximizes the likeli-
hood function and yields the largest difference
between individuals from the 2 age groups (data not
shown). Because the literature commonly reports cat-
egories based around 60 years of age, we also analyzed
the data using age 60 years as the cut-off point. These
analyses produced similar results (data not shown).
Comparisons of the 2 age groups and assessment of
other potential risk factors for outcomes of interest
were done using multivariate Cox proportional haz-
ards regression analysis [19]. Age group ($55 years
versus \55 years) was forced into all Cox models.
Other variables considered in the analysis included
sex, Karnofsky performance score at transplant
(\90% versus$90%), disease stage at diagnosis (stage
I/II versus III/IV), presence versus absence of B symp-
toms, disease status at transplant, interval from diag-
nosis to transplant (\12 months versus $12
months), type of graft (bone marrow versus peripheral
blood), use of involved-field radiation, conditioning
regimen (no total body irridiation [TBI] versus TBI),
year of transplant, use of purging, and use of
granulocyte-colony stimulating factor (G-CSF) or
granulocyte macrophage colony stimulating factorP
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Figure 4. Cumulative incidence of DFS and OS after autologous HCTs
for follicular grade III/diffuse large B cell/immunoblastic NHL patients
aged\55 years versus $55 years.
Table 2A. Multivariate Analysis of Treatment-Related Mor-
tality for Follicular Grade I/II NHL
Variables N
Relative Risk of
TRM (95% CI) P-value
Main effect of age
<55 595 1.00 .54
$ 55 168 1.18 (0.69-2.02)
Other significant covariates
Type of graft <.001*
Bone marrow 221 1.00
Peripheral blood†
Within first 12 months after transplant 235 0.26 (0.14-0.48) <.001
Beyond first 12 months after transplant 307 1.26 (0.61-2.60) .54
Conditioning regimen
No TBI 434 1.00 .014
TBI 329 1.75 (1.12-2.72)
TBI indicates total body irridiation; TRM, treatment-related mortality;
CI, confidence interval; HCT, hematopoietic cell transplantation, NHL,
non-Hodgkin lymphoma.
*Two degrees of freedom test.
†Time-dependent covariates. The effect of peripheral blood graft type
on outcome differs with the length of time after transplant. The risk
of TRM is lower for recipients of peripheral blood grafts within the first
12 months following HCT compared to bone marrow recipients, but no
different in the period beyond 12 months after HCT.
Table 2B. Multivariate Analysis of Treatment-Related Mor-
tality for Follicular Grade III/Diffuse Large B Cell/Immuno-
blastic NHL
Variables N
Relative Risk
of TRM (95% CI) P-Value
Main effect
of age
<55 1294 1.00 <.001
$55 615 1.86 (1.43-2.43)
Other significant covariates
Karnofsky performance
score at transplant*
(1) $90% 1167 1.00 .003†
(2) <90% 692 1.59 (1.20-2.04) .001
(3) Missing 50 1.04 (0.50-2.17) .26
Disease status
at transplant‡
(1) CR1 221 1.00 <.001§
(2) PIF-sensitive 293 1.35 (0.77-2.38) .30
(3) PIF-resistant 98 1.39 (0.61-3.14) .44
(4) REL-sensitive 570 1.17 (0.69-1.98) .56
(5) REL-resistant 155 3.35 (1.88-5.95) <.001
(6) CR2+ 324 1.65 (0.96-2.81) .07
(7) REL-untreated/unknown 75 2.17 (1.07-4.39) .032
(8) PIF-untreated/unknown 15 4.43 (1.52-12.96) .007
(9) Unknown 158 1.70 (0.92-3.14) .09
Time from
diagnosis to transplant
<12 months 759 1.00 .040
$12 months 1150 1.41 (1.02-1.95)
Use of purging
No 1771 1.00 .008
Yes 138 1.77 (1.16-2.68)
G-CSF or GM-CSF to
promote engraftment
No 449 1.00 .017†
Yes¶
Within first 8 months
after transplant
800 0.69 (0.49-0.98) .039
Beyond first 8 months
after transplant
660 1.70 (0.99-2.92) .054
CR indicates complete remission; PIF, primary induction failure; G-CSF,
granulocyte-colony stimulating factor; GM-CSF, granulocyte-macro-
phage colony stimulating factor; TRM, treatment-related mortality;
NHL, non-Hodgkin lymphoma.
*Other pairwise comparisons: P23 5 .91.
†Two degrees of freedom.
‡Other significant pairwise comparisons: P45$ .001; P485 .012; P525 .001;
P53 5 .028; P56 5 .003; P59 5 .019; P74 5 .046; P82 5 .027.
§Eight degrees of freedom.
¶Time-dependant covariates. The effect of G-CSF or GM-CSF to pro-
mote engraftment differs with the length of time after transplant. The
risk of TRM is lower for recipients with G-CSF or GM-CSF to promote
engraftment within the first 8 months following HCT compared to re-
cipients who did not receive G-CSF or GM-CSF, but no different in
the period beyond 8 months after HCT.
Biol Blood Marrow Transplant 14:1323-1333, 2008 1327Autologous HCTs in Elderly Lymphoma(GM-CSF) to promote engraftment (defined as initia-
tion of these therapies within 7 days of HCT).
Overall completeness index follow-up is 92% (\55
5 91%; $55 5 94%). To accommodate the physio-
logic differences between histologies, separate analyses
were performed for indolent and aggressive lymphoma
histologies. For all outcomes of interest, the assump-
tion of proportional hazards was tested using time-
dependent covariates and graphical methods [20].
For relapse and treatment failure, all covariates consid-
ered in the multivariate analyses satisfied the propor-
tionality assumption, for both histology types. For
OS, nonproportional hazards were identified for
Karnofsky performance score at transplant (indolent
histology patients) and interval from diagnosis to
transplant (aggressive histology patients). Cox regres-
sion models for OS were thus stratified by the Karnof-
sky performance score or interval from diagnosis to
transplant, according on histology type. For TRM,
nonproportional hazards were identified for type of
graft (indolent histology patients) and use of G-CSF
or GM-CSF (aggressive histology patients). There-
fore, type of graft was entered into the Cox model
for TRM for indolent NHL model as a time varying
covariate, with early (\12 months) and late ($12
months) effects for peripheral blood. Similarly, G-
CSF or GM-CSF to promote engraftment was entered
into the TRM for aggressive NHL model as a time
varying covariate, with early (\8 months) and late
($8 months) effects for recipients who received
growth factors. The 8 Cox models were built using
a forward stepwise selection process and covariates
that attained a value of P# .05 were considered statis-
tically significant and held in the final model (againwith the exception that age group was forced into all
models). For all outcomes of interest, interactions be-
tween age group and all covariates were tested before
and after the model building. For relapse, there was
a significant interaction between year of transplant
and the effect of age for indolent NHL. In other
words, age had a different effect depending on whether
the patient was transplanted between 1990 and 1994,
1995 and 1996, 1997 and 1998, or 1999 and 2000.
Therefore, the comparisons between age groups for
this model are presented separately for each year of
Table 3A. Multivariate Analysis of Relapse for Follicular
Grade I/II NHL
Variables N
Relative Risk
of Relapse (95% CI) P-Value
Main effect of age*
Year of transplant: 1990-1994
Age $55 versus <55 375 1.35 (0.95-1.94) .10
Year of transplant: 1995-1996
Age $55 versus <55 170 0.76 (0.48-1.21) .25
Year of transplant: 1997-1998
Age $55 versus <55 143 1.12 (0.69-1.82) .64
Year of transplant: 1999-2000
Age $55 versus <55 75 2.66 (1.32-5.37) .006
Other significant covariates
Disease status at transplant†
(1) CR1 97 1.00 <.001‡
(2) PIF-sensitive 141 1.66 (1.13-2.45) .010
(3) PIF-resistant 22 3.23 (1.79-5.81) <.001
(4) REL-sensitive 209 1.93 (1.35-2.77) <.001
(5) REL-resistant 46 2.58 (1.62-4.11) <.001
(6) CR2+ 125 1.16 (0.77-1.75) .47
(7) REL-untreated/unknown 29 1.44 (0.82-2.53) .20
(8) PIF-untreated/unknown 10 1.80 (0.70-4.59) .22
(9) Unknown 84 1.35 (0.86-2.11) .19
CR indicates complete remission; PIF, primary induction failure; NHL,
non-Hodgkin’s lymphoma; CI, confidence interval.
Additional tests:
1. Overall 1 degree of freedom test for age ($55 versus <55): P5 .006.
2. Overall 3 degree of freedom test for year of transplant: P 5 .002.
3. Overall 3 degree of freedom test for Age  Year of transplant: P 5
.027.
*There is a significant interaction between the effects of age and year of
transplant on the risk of relapse (P5 .03) such that the effect age differs
with the year of transplant.
†Other significant pairwise comparisons: P23 5 .016; P26 5 .040; P36 #
.001; P39 5 .004; P46 5 .001; P52 5 .036; P56 # .001; P59 5 .007; P73 5
.020; P75 5 .049.
‡Eight degrees of freedom.
Table 3B. Multivariate Analysis of Relapse for Follicular
Grade III/Diffuse Large B Cell/Immunoblastic NHL
Variables N
Relative Risk
of relapse (95% CI) P-value
Main effect of age
<55 1294 1.00 .002
$55 615 1.22 (1.08-1.38)
Other significant covariates
Disease status at transplant*
(1) CR1 221 1.00 <.001†
(2) PIF-sensitive 293 2.28 (1.76-2.95) <.001
(3) PIF-resistant 98 4.07 (2.98-5.55) <.001
(4) REL-sensitive 570 2.34 (1.85-2.97) <.001
(5) REL-resistant 155 4.08 (3.07-5.43) <.001
(6) CR2+ 324 1.34 (1.03-1.74) .031
(7) REL-untreated/unknown 75 2.44 (1.72-3.46) <.001
(8) PIF-untreated/unknown 15 1.72 (0.75-3.93) .20
(9) Unknown 158 2.62 (1.97-3.48) <.001
CR indicates complete remission; PIF, primary induction failure; NHL,
non-Hodgkin’s lymphoma; CI, confidence interval.
*Other significant pairwise comparisons: P23 # .001; P26 # .001; P36 #
.001; P39 5 .004; P43 # .001; P45 # .001; P46 # .001; P52 # .001; P56 #
.001; P585 .040; P595 .001; P735 .005; P755 .003; P76# .001; P835 .04;
P96 # .001.
†Eight degrees of freedom.
1328 Biol Blood Marrow Transplant 14:1323-1333, 2008H. M. Lazarus et al.transplantation (see Table 3A). Overall, covariate ef-
fects were tested using Wald test. All computations
were made using the procedures PHREG and
TPHREG in the statistical package SAS Version 9.1
for Unix. All multivariate models were examined for
center effects using a random effects or frailty model
[21]; there were no significant center effects.RESULTS
Table 1 shows the patient-, disease-, and trans-
plant-related characteristics of the 2754 patients in-
cluded in the study according to age group ($55
years versus\55 years) and histology type. The me-
dian age in the 2 age groups was 61 years (range: 55-
73 years) and 45 years (range: 18-55 years) respectively,
and younger patients were more likely to have follicu-
lar lymphoma (32% versus 21%). Combining patients
from the 2 histology types, Karnofsky performance
score at transplant did not differ significantly, but
younger patients were more likely to have B symptoms
at diagnosis (38% versus 31%), have primary refrac-
tory disease (24% versus 15%), receive bone marrow
rather than peripheral blood as the graft source (30%versus 19%), and undergo a TBI-containing regimen
(31% versus 22%).
Figures 1 and 2 show the univariate probabilities of
all outcomes of interest after transplantation according
to age group for indolent histology patients. At 1-, 3-
and 5-years after transplant younger patients had
a lower probability of relapse and a higher probability
of DFS and OS. At 5 years after transplant, TRM did
not differ significantly between age groups, but re-
lapses were significantly higher, 8% versus 7% and
55% versus 63%, for subjects\55 years versus $55
years, respectively. DFS and OS rates at 5 years also fa-
vored younger patients, 37% versus 29% and 60% and
54%, respectively, Similarly, the younger aggressive
histology patients had a lower probability of TRM
and relapse and a higher probability of DFS and OS
compared to subjects age .55 years (Figures 3 and
4). Specifically, at 5 years, TRM rates were signifi-
cantly lower in younger patients (9% versus 15%) as
were relapse rates (59% versus 66%), respectively.
Correspondingly, DFS and OS rates were superior in
the younger patient population, 32% versus 19% and
47% versus 30%, respectively.
Tables 2A and B show the multivariate analysis of
TRM for older versus younger patients in both histo-
logic subgroup types, respectively. After adjusting for
other covariates, aggressive histology patients 55 years
and older were 1.86 times more likely to have TRM
than younger patients (95% confidence interval [CI]
1.43-2.43, P\ .001). Age, however, was not a factor
in the indolent histology group (P5 .54). Other factors
found to be associated with an increased TRM in the
more aggressive histology patients were poor perfor-
mance status, chemoresistant disease before transplant,
Table 4A. Multivariate Analysis of Overall Survival for Fol-
licular Grade I/II NHL*
Variables N
Relative Risk
of Death (95% CI) P-Value
Main effect of age
<55 615 1.00 .024
$55 173 1.33 (1.04-1.71)
Other significant covariates
Disease status at transplant†
(1) CR1 101 1.00 <.001‡
(2) PIF-sensitive 145 1.39 (0.90-2.14) .14
(3) PIF-resistant 22 2.89 (1.53-5.46) .001
(4) REL-sensitive 218 1.82 (1.23-2.71) .003
(5) REL-resistant 47 3.27 (1.99-5.39) <.001
(6) CR2+ 129 1.44 (0.92-2.23) .11
(7) REL-untreated/unknown 32 1.48 (0.83-2.65) .19
(8) PIF-untreated/unknown 10 3.31 (1.44-7.58) .005
(9) Unknown 84 2.09 (1.32-3.33) .002
Year of transplant§
(1) 1999-2000 81 1.00 .005¶
(2) 1990-1994 383 2.08 (1.32-3.28) .002
(3) 1995-1996 174 1.54 (0.95-2.51) .080
(4) 1997-1998 150 1.74 (1.05-2.87) .030
CR indicates complete remission; PIF, primary induction failure; NHL,
non-Hodgkin lymphoma; CI, confidence interval.
*This Cox model was stratified on Karnofsky performance score at
transplant (ie, $90% and <90%).
†Other significant pairwise comparisons: P23 5 .014; P29 5 .045; P36 5
.021; P455 .004; P52# .001; P56# .001; P755 .008; P825 .03; P865 .040.
‡Eight degrees of freedom.
§Other pairwise comparisons: P23 5 .027; P24 5 .24; P34 5 .49.
¶Three degrees of freedom.
Table 4B. Multivariate Analysis of Overall Survival for Fol-
licular Grade III/Diffuse Large B Cell/Immunoblastic NHL*
Variables N
Relative Risk
of Death (95% CI) P-Value
Main effect of age
<55 1334 1.00 <.001
$ 55 632 1.50 (1.33-1.69)
Other significant covariates
Karnofsky performance score
at transplant†
(1) $90% 1200 1.00 <.001‡
(2) <90% 712 1.35 (1.20-1.54) <.001
(3) Missing 54 0.93 (0.67-1.32) .038
Disease status at transplant§
(1) CR1 228 1.00 <.001¶
(2) PIF-sensitive 305 1.60 (1.23-2.07) <.001
(3) PIF-resistant 100 3.09 (2.27-4.21) <.001
(4) REL-sensitive 586 1.92 (1.50-2.45) <.001
(5) REL-resistant 159 3.94 (2.98-5.21) <.001
(6) CR2+ 330 1.54 (1.17-2.02) .002
(7) REL-untreated/unknown 78 2.51 (1.79-3.52) <.001
(8) PIF-untreated/unknown 16 1.85 (0.96-3.57) .07
(9) Unknown 164 2.36 (1.78-3.15) <.001
Conditioning regimen
No TBI 1526 1.00 .009
TBI 440 1.20 (1.05-1.37)
Year of transplantt
(1) 1999-2000 295 1.00 .008**
(2) 1990-1994 696 1.36 (1.13-1.65) .002
(3) 1995-1996 499 1.24 (1.02-1.52) .032
(4) 1997-1998 476 1.14 (0.93-1.40) .20
CR indicates complete remission; PIF, primary induction failure; NHL,
non-Hodgkin lymphoma; TBI, total body irradiation, CI, confidence in-
terval.
*This Cox model was stratified on interval from diagnosis to transplant
(ie, $12 months and <12 months).
†Other pairwise comparisons: P23 5 .70.
‡Two degrees of freedom.
§Other significant pairwise comparisons: P23 # .001; P29 5 .002; P36 #
.001; P43 # .001; P45 # .001; P46 5 .016; P52 # .001; P56 # .001; P58 5
.022; P59 # .001; P72 5 .004; P75 5 .004; P76 5 .001; P96 < .001.
¶Eight degrees of freedom.
tOther pairwise comparisons: P23 5 .22; P24 5 .025; P34 5 .31.
**Three degrees of freedom.
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use of purging. For the indolent histology patients, sig-
nificant covariates for increased TRM included use of
bone marrow rather than blood as the graft source
(however, this effect was no longer statistical significant
in patients surviving .12 months posttransplant) and
a TBI-containing conditioning regimen.
Tables 3A and B show the multivariate analysis of
relapse. There was a statistically significant increase in
risk of relapse for older patients ($55 years) among pa-
tients with more aggressive NHL histologies (relative
risk [RR] 1.22, 95% CI 1.08-1.38, P5 .002). However,
older patients with indolent histologies had an in-
creased risk of relapse only if they were transplanted
in the time period of 1999 to 2000. After adjusting
for other covariates, both the indolent and the aggres-
sive lymphoma histology patients with primary induc-
tion failure (PIF) and relapsed disease were at
increased risk for lymphoma recurrence.
Similar results were noted for treatment failure (ie,
inverse of DFS) for both histologic groups for the effect
of age (a consistent effect confined to the aggressive
subtype) and disease status at transplant. For the indo-
lent histology group, age did not affect treatment fail-
ure (inverse of DFS), but disease status at transplant
was the major determinate of outcome. The relative
risk of treatment failure (95% CI) was significantly
higher for patients who were primary induction failure
sensitive (1.64 [1.15-2.32] times, P 5 .006), primaryinduction failure resistant (2.74 [1.59-4.73]
times, P \ .001], relapse sensitive (1.93 [1.39-2.68]
times, P \ .001), and relapse resistant (2.55 [1.66-
3.93] times, P\ .001). On the other hand, older age ag-
gressive NHL patients were 1.32 (1.18-1.48) times
more likely to fail than younger patients. Similar to
the indolent NHL population, disease status at trans-
plant again was a major determinant of outcome. The
relative risk of treatment failure (95% CI) was signifi-
cantly higher for patients who were primary induction
failure sensitive (2.03 [1.61-2.56] times, P \ .001),
primary induction failure resistant (3.43 [2.57-4.58]
times, P \ .001), relapse sensitive (2.11 [1.71-2.61]
times,P\.001) relapse resistant (3.89 [3.01-5.02] times,
P \ .001), and with second CR or beyond (1.47
[1.16-1.86] with times, P 5 .001). The use of TBI in
the conditioning regimen and poor performance status
were associated with a statistically significant increase
in treatment failures in the aggressive lymphoma
subgroup (1.16 [1.02-1.31], P5 .027).
Table 5. Characteristics of NHL Patients More Than Age 65
Years Undergoing Autologous HCT from 1990 to 2000 and
Reported to the CIBMTR
Variable N (%)
Number of patients 149
Age, median (range), years 67 (65-73)
Male sex 71 (48)
Karnofsky performance score at transplant
<90 61 (41)
$90 87 (59)
Missing 1
Histology
Follicular grade I/II 21 (14)
Follicular grade III/DLBCL/Immunoblastic
NHL
128 (86)
Disease stage at diagnosis
I or II 59 (40)
III or IV 87 (58)
Unknown 3 ( 2)
B symptoms at diagnosis
Absent 91 (61)
Present 40 (27)
Unknown 18 (12)
Disease status at transplant
CR1 10 ( 7)
CR2+ 33 (24)
PIF-sensitive 18 (13)
PIF-resistant 2 ( 1)
REL-sensitive 48 (35)
REL-resistant 15 (11)
REL-untreated/unknown 13 ( 9)
Missing 10
Chemosensitivity at transplant
Sensitivity 109 (73)
Resistant 24 (16)
Untreated/not evaluable/unknown 16 (11)
Interval from diagnosis to transplant
<12 months 34 (23)
$12 months 115 (77)
Graft type
Bone marrow 17 (11)
Peripheral blood 132 (89)
Use of involved-field radiation 6 ( 4)
Use of TBI 19 (13)
Year of transplantation
1990-1994 21 (14)
1995-1996 32 (22)
1997-1998 54 (36)
1999-2000 42 (28)
In vitro purging performed 10 ( 7)
G-CSF or GM-CSF to promote engraftment 134 (90)
New malignancy
Solid tumor 3 ( 2)
Skin cancer 1 ( 1)
New malignancy, not specified 5 ( 3)
None 140 (94)
Median follow-up of survivors, months 69 (3-139)
CR inidicates complete remission; PIF, primary induction failure; TBI , to-
tal-body irradiation; GF, growth factors; G-CSF, granulocyte-colony
stimulating factor; GM-CSF, granulocyte-macrophage colony stimulating
factor; NHL, non-Hodgkin lymphoma; CIBMTR, Center for Interna-
tional Blood and Marrow Transplant Research.
Table 6. Univariate Probabilities of Outcomes for NHL
Patients More Than Age 65 Years Undergoing Autologous
HCT from 1990 to 2000
Outcome Event N Prob (95% CI)*
Treatment-related mortality 147
@ 1 year 11 (7-17)
@ 3 years 13 (8-19)
@ 5 years 14 (9-20)
Relapse 147
@ 1 year 60 (51-67)
@ 3 years 66 (58-73)
@ 5 years 66 (58-73)
Disease-free survival 147
@ 1 year 29 (22-36)
@ 3 years 21 (15-28)
@ 5 years 20 (14-27)
Overall survival 149
@ 1 year 50 (42-58)
@ 3 years 35 (28-43)
@ 5 years 29 (22-37)
PROB indicates probability; CI, confidence interval.
*Probabilities of treatment-related mortality and relapse were calcu-
lated using the cumulative incidence estimate. Disease-free survival
and overall survival were calculated using the Kaplan-Meier product
limit estimate.
Table 7. Causes of Death for NHL Patients Undergoing
Autologous HCT from 1990 to 2000 Comparing <55 versus
>55 Years of Age
#55 Years >55 Years
Causes of death N (%) N (%)
Number of patients 1032 544
Primary disease 729 (71) 370 (68)
New malignancy 23 ( 2) 18 ( 3)
Graft-versus-host disease 5 (<1) 0
Interstitial pneumonia 48 (5) 32 (6)
Infection 48 (5) 30 (6)
Organ failure 55 (5) 41 (8)
Other cause 124 (12) 53 (9)
NHL indicates non-Hodgkin lymphoma; HCT, hematopoietic cell trans-
plantation.
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OS for the main effect of age. The relative risk of death
was higher in older patients ($55 years) in indolent
histology as well as in aggressive NHL patients. After
adjusting for other covariates, risk of mortality was sta-
tistically significantly increased in patients whose dis-
ease was not controlled (relapse or primary inductionfailure). Again, the use of TBI in the conditioning reg-
imen and poor performance status were associated
with a statistically significant increase in mortality in
the aggressive lymphoma subgroup.
We further explored outcome in the oldest patient
population, that is, N5 149 subjects aged over 65 years
(Table 5). Compared to those patients\65 years (N5
2605), older individuals were statistically more likely to
have a lower performance status (P 5 .044), have ag-
gressive rather than indolent histologies (P \.001),
have more advanced disease stage (P 5 .032), yet
more sensitive disease (P 5 .002), and undergo HCT
beyond 12 months after diagnosis (P 5 .002). Table 6
shows the univariates for the 4 outcomes of interest
for the older patient group. At 5 years after HCT, prob-
abilities of TRM and relapse were 14% (95% CI 9-20)
and 66% (95% CI 58-73), respectively. These data
translate into 5-year DFS and OS probabilities of
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tively. Table 7 shows causes of death for all patients us-
ing age 55 years as the breakpoint. The major cause of
death in both age groups was recurrent lymphoma.DISCUSSION
We report the outcomes and prognostic factors for
2754 patients with NHL who received autologous
stem cell transplant between 1990 and 2000 and were
reported to the CIBMTR, based on age groups older
or\55 years. In multivariate analysis, older patients
with more aggressive NHL histologies were 1.86 times
more likely than younger patients to experience TRM.
Outcomes reported in this study appear better than the
considerably smaller series of patients with aggressive
NHL histologies reported in the literature [22-29],
some of which included aggressive [21-23,27] versus
mixed indolent and aggressive [25-27,29] histologies.
It should be noted that in many of these reports, in-
cluding those by Bitran and colleagues [28] and
Moreau and coworkers [24], the transplant was per-
formed only if the patient had relapsed disease that
was sensitive to salvage therapy. With the exception
of Sweetenham et al. [22], all these authors used 60
years as their age cutoff. Although 55 years is a more
optimal choice for our data, the analyses of Tables
2A/B-4A/B were repeated with 60 years as the age
threshold. Although the point estimates for the effect
of age varied slightly, the overall effect of age remained
the same, as did the other significant covariates (data
not shown). Further, in our series, TRM at up to 5
years did not exceed 8% for either age group for follic-
ular grade I/II NHL patients.
Our observational database collects information
prospectively and such data likely are a more represen-
tative reflection of the practice of HCT in the commu-
nity. It is difficult to make effective comparisons
between our results and those reported in the literature
for these patients. Published results from single center
studies are often unadjusted (univariate outcomes), and
study entry criteria, treatment, and attribution of cause
of death are likely to vary across centers and studies. As
well, the observational data collected by CIBMTR
may include patients previously reported in single cen-
ter experiences. Our reported 6% TRM at 1 year and
7% at 3 years for the indolent histology group for
both older and younger patients compares favorably
with the experiences reported in the 2 largest series
[22,27], although these communications included
mostly aggressive histologies. In the aggressive NHL
patients, TRM rates at 3 years and 5 years after trans-
plant of 14% (95% CI 11-17) and 15% (95% CI 12-18),
respectively, in the over 55-year age group compare
favorably with the 22.4% reported by Gopal et al
[27]. Those investigators reported both infectious
and noninfectious events as causes of death, the formerpostulated to be because of a protracted time to im-
mune reconstitution in the older patients. Further,
for patients.55 years, the lower TRM in the indolent
population compared to the aggressive histology
group may reflect an inherent selection bias, that is,
other therapeutic options may be available for elderly
indolent NHL patients. As anticipated, poor perfor-
mance status at transplant and a longer time from diag-
nosis to transplant was associated with a toxic death.
The adverse effect of hematopoietic growth factor
use in this patient population has been previously de-
scribed [30]. Data from the European Group for Blood
and Marrow Transplantation (EBMT) and reported
by Sweetenham et al [22] described a 38% TRM for
patients aged .55 years. A comparison within the
EBMT database for the patients aged \55 years
showed a significantly lower TRM, 12% versus 38%
(P 5 .03). On the other hand, in our series those sub-
jects aged\55 years had a reduced TRM of 9% at 3
years (95% CI 7-10) as well as at 5 years (95% CI 7-
11). Use of bone marrow rather than blood as the
stem cell source and use of a TBI-containing regimen
portended for TRM in patients with the aggressive
lymphoma histology. The EBMT also reported that
TBI-based preparative regimens contributed to
a higher toxic death rate [22].
We also demonstrated that risk of relapse was
greater for all older patients in the more aggressive his-
tologic group, but only for older patients transplanted
between 1999 and 2000 in the indolent histologic
group. As anticipated, advanced or persistent disease
in both indolent and aggressive histologic patient pop-
ulations was associated with an increased risk of relapse
compared to remission. Similarly, chemotherapy resis-
tance prior to transplant was associated with an in-
creased risk of relapse.
These data show that older patient age was associ-
ated with a statistically significant increased risk of
treatment failure only in the aggressive histology sub-
set (1.32-fold increase, P\ .001) compared to the in-
dolent histology group; however, in both groups age
$55 years was associated with increased mortality
(RR 1.50, P\ .001 and RR 1.33, P 5 .024, respec-
tively). Other factors associated with treatment failure
and increased death in both patient populations in-
cluded persistent, relapsed, or chemoresistant disease.
Gopal and colleagues [27] reported superior survival in
patients with responsive, relapsed disease as OS at 4
years was 39% in sensitive disease versus only 15%
in resistant NHL. In the aggressive histologic group,
poor performance status as well as use of TBI in the
preparative regimen significantly increased the risk of
treatment failure and reduced OS. Our data did not in-
dicate that blood rather than bone marrow as the graft
source was associated with an improved OS, in con-
trast to the European experience generated in ad-
vanced Hodgkin and high-grade NHL patients [31].
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account for patients who may not have been consid-
ered for HCT, that is, careful selection and exclusion
of older patients deemed unfit for HCT. Also, per-
haps other inherent selections biases are in operation
such as offering HCT only for follicular NHL pa-
tients with highly aggressive disease who are young
versus designating the older patients for other thera-
pies, for example, age and disease biologic behavior
discrimination. Another limitation of this report is
the observation that various histologic classifications
were in use during this long period of patient accrual
and follow-up. All studies are subject to changing
lymphoma classification over time, but the histologies
noted were those reported by each institution and the
diagnoses are consistent within the era of HCT. Pa-
thology materials are not routinely subject to second-
ary review.
After adjusting for other important characteristics,
older patients transplanted between 1990 and 2000
have a greater risk of adverse outcomes than those
\55 years. Although changes in transplantation have
allowed more advanced age patients to be considered
for HCT, these patients have worse outcomes com-
pared to their younger counterparts. Despite this ob-
servation, some older patients still should be
considered for potential cure using HCT. Buadi and
colleagues [32] at the Mayo Clinic reported a series
of 93 intermediate-grade NHL patients at least 60
years of age (including 24 over age 70 years) who un-
derwent HCT. TRM was 5.4% and 4-year event-
free survival (EFS) was 38%, results that did not differ
from a cohort less than age 60 years (2.2% and 42%,
P 5 .10, respectively). Although a small series from a
single institution, this group showed that good results
can be obtained in older patients using careful patient
selection and a non-TBI regimen. Another recent sin-
gle institution trial reported by Wildes and colleagues
[33] showed similar toxicities and survival for patients
older than 60 years compared to younger patients.
These investigators observed that after controlling
for age, comorbidities significantly influenced OS.
The 149 patients age .65 years described herein
were more likely to have a worse performance status,
more advanced disease, and a more aggressive histol-
ogy compared to their younger counterparts in our
data set. Such information may help account for the
14% (95% CI 11-19) 5-year TRM. This patient group
also had lower 5-year DFSs and OSs, 20% (95% CI
14-27) and 29% (95% CI 22-37), respectively. Seventy
percent of elderly patients died because of lymphoma,
a rate essentially the same as in the younger patients
(69%). A series of 99 consecutive relapsed NHL pa-
tients age older than 65 years reported recently by
Hosing and coworkers [34] showed an 8% cumulative
nonrelapse mortality at 26 months and a 61% 3-year
OS. They found that even elderly patients with acomorbidity index .2 had acceptable outcomes but
were at higher risk for developing significant toxicity.
Additional strategies to reduce these risks for TRM
and relapse should be explored. Possible strategies
could include individual patient dosing as employed
with busulfan-containing regimens in the allograft set-
ting [35], and use of targeted radioimmunoconjugates,
which may facilitate effective delivery of radiation to
tumor cells without causing excessive toxic effect to
normal tissues [36,37]. Ultimately, these and other ap-
proaches in older patients require further study.ACKNOWLEDGMENTS
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